You are placing too much emphasis on a conference, and not enough emphasis on readiness for regulatory interactions, potential commercialization launch, potential Ind submission(s), potential trial launch(es),potential clinic openings for leukapheresis and/or patients treatment, collaborations, NICE/CDF submissions, funding, etc.
You would be a terrible CEO to redirect management away from all hands on deck, or, alternatively having kids hand out flyers at ASCO. Just stop and think for a red hot moment.
Market Data 
Markets 
AI
